Please login to the form below

Not currently logged in
Email:
Password:

Back to Results


Finalist

The Value of Targeted Therapies - a Case Study in Defining, Documenting and Delivering Value in Severe Eosinophilic Asthma (SEA)

by Teva Respiratory


Summary of work

Imagine not being able to catch your breath - all day, almost every day - despite taking a complete regimen of treatments for your asthma, while being managed by a top asthma specialist. Severe asthma with eosinophilia, a debilitating phenotype, has a devastating impact on patients, contributing to increased direct healthcare and indirect societal costs.1,2 CINQAERO® (reslizumab) is an approved anti-IL-5 add-on treatment for patients with eosinophilia and inadequately-controlled asthma despite standard-of-care. It rapidly reduces eosinophils, significantly reduces exacerbations, increases lung function and improves quality of life.3 Reslizumab enables patients to take back control of their lives, with the expectation of long-term economic and societal value.

To allow patients access to reslizumab, Teva provided transparent clinical-effectiveness and cost-effectiveness evidence for several rigorous health technology assessments (HTA) agencies, including NICE and G-BA.

For the NICE dossier, Teva proposed the use of reslizumab in patients with three or more severe exacerbations in previous year, a broader patient population than recommended in the past. Teva demonstrated that this is an optimal patient population for reslizumab and that there is unmet need for broader access.

This resulted in NICE and G-BA recommending reslizumab, enabling patients with the greatest need to access an effective, targeted treatment -reslizumab.

Judges' comments

This touching programme cleverly captured health economics, indirect patient burden and social impact. The involvement from patient associations was a splendid touch. This submission really resonated with us and Teva should be commended for it.